BANYAN BIOMARKERS, INC.
SAN DIEGO, CA · Founded 2010 · CIK 0001581877 · Medtech · Acquired
Serum biomarker assays measuring UCH-L1 and GFAP proteins to stratify neonates with hypoxic ischemic encephalopathy and predict response to hypothermia treatment
- Grants
- $150K
- 1 award
- Sector median: 1
- Raised
- $14M
- 5 Form D · Jun 2020
- 76 months since last filing
- Contracts
- $62M
- 14 awards · Defense
- #14 of 4531 in medtech
- Patents
- 39
- 9 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2009201120132015201720192021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Defense · Banyan Biomarke | $20,865 | |
| Federal contract | Department of Defense · Consultant | $22,441 | |
| Federal contract | Department of Defense · Antibody/protein | $10,410 | |
| Federal contract | Department of Defense · Advanced Development | $57,333,246 | |
| Federal contract | Department of Defense · Antibodies | $18,790 | |
| Federal contract | Department of Defense · Analysis Of Rat Plasma Samples | $3,520 | |
| Federal contract | Department of Defense · Altitude Study | $50,000 | |
| Federal contract | Department of Defense · Consultant | $18,900 | |
| Federal contract | Department of Defense · Tbi Samples | $7,600 | |
| Federal contract | Department of Defense · Antibodies | $10,475 | |
| Federal contract | Department of Defense · Collect Blood Samples&clinical Data | $125,000 | |
| Private capital raised | Form D · SEC | $5,999,998 | |
| Private capital raised | Form D · SEC | $1,999,999 | |
| Federal contract | Department of Defense · Igf::ot::igf Research And Development | $3,708,139 | |
| Private capital raised | Form D · SEC | $1,808,145 | |
| Federal grant | Department of Health and Human Services · Phase I · Clinical utility of serum biomarkers for the management of neonatal Hypoxic Ischemic Encephalopathy (HIE) on a point-of-care device | $150,001 | |
| Federal contract | Department of Defense · Evaluate Samples For Gfap (PROT#1796)IGF::CT::IGF | $90,250 | |
| Federal contract | Department of Defense · Obtain All Banyan Biomarkers, Inc. Brain Trauma Indicator (bti) Kits And Perform On-site Bti Protocol Specific Training In Preparation For The Conduct Of Clinical Research To Aid In The Determination Of Service Members Sustaining Traumatic Brain Injury (tbi) Using Banyan Biomarkers, Inc. Software And Hardware Systems Previously Acquired By The Government. | $515,327 | |
| Private capital raised | Form D · SEC | $2,225,847 | |
| Private capital raised | Form D · SEC | $2,265,419 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 11 | Stratatech Corporation | $98M | $3.0M |
| 12 | RAPISCAN LABORATORIES, INC. | $68M | — |
| 13 | SELUX DIAGNOSTICS, INC. | $63M | $124M |
| 14 | BANYAN BIOMARKERS, INC. | $62M | $14M |
| 15 | FIREFLY NEUROSCIENCE, INC. | $56M | $19M |
| 16 | RIVANNA MEDICAL, INC. | $52M | $370K |
| 17 | Visby Medical, Inc. | $52M | $235M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Herbert BoyerDirector
- Michael Catania, PhDExecutive Officer
- Nancy Denslow, PhDDirector
- Nancy Denslow, Ph.D.Director
- Luis De TaboadaExecutive Officer
- David FlaggDirector
- Norman FlaggDirector
- Tony GroverExecutive Officer
- Ronald Hayes, PhDDirector · Executive Officer
- Ronald Hayes, Ph.D.Director · Executive Officer · Promoter
- Henry NordhoffDirector · Executive Officer
- Andrew ParkerDirector
- Julie PashkowskyExecutive Officer
- Steven RichieriDirector · Executive Officer
- William Roper, Jr.Director
- Jackson StreeterDirector · Executive Officer
- Jackson Streeter, M.D.Director · Executive Officer
- Frederic SweeneyDirector
- Andrew von Eschenbach, MDDirector
- Andrew von Eschenbach, M.D.Director
- Stanford WarshawskyDirector
Patents
- Biomarker Detection Process And Assay Of Neurological Conditiongranted
- Antibodies To Ubiquitin C-terminal Hydrolase L1 (UCH-L1) And Glial Fibrillary Acidic Protein (gfap) And Related Methodsapplication
- Antibodies To Ubiquitin C-terminal Hydrolase L1 (UCH-L1) And Glial Fibrillary Acidic Protein (gfap) And Related Methodsgranted
- Biomarker Detection Process And Assay Of Neurological Conditiongranted
- Neural Proteins As Biomarkers For Nervous System Injury And Other Neural Disordersapplication
- Neural Proteins As Biomarkers For Nervous System Injury And Other Neural Disordersgranted
- Antibodies To Ubiquitin C-terminal Hydrolase L1 (UCH-L1) And Glial Fibrillary Acidic Protein (gfap) And Related Methodsgranted
- Compositions And Methods Relating To Argininosuccinate Synthetasegranted
- Neural Proteins As Biomarkers For Nervous System Injury And Other Neural Disordersgranted
- Micro-rna, Autoantibody And Protein Markers For Diagnosis Of Neuronal Injuryapplication
- Biomarker Assay Of Neurological Conditionapplication
- Micro-rna, Autoantibody And Protein Markers For Diagnosis Of Neuronal Injurygranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.